Using translational medicine to understand clinical differences between botulinum toxin formulations.
about
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical PracticeChange of distribution and timing of bite force after botulinum toxin type A injection evaluated by a computerized occlusion analysis system.Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus--part 2.Botulinum toxin type A products are not interchangeable: a review of the evidence.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasmA new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteinsClinical and translational medicine: Integrative and practical scienceBotulinum neurotoxin type A in facial aesthetics.Upper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus--part 1.The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limbBotulinum toxin A treatment of the lower extremities in children with cerebral palsy.Use of botulinum toxin A in management of children with cerebral palsy.Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.The use of botulinum toxin and epidural analgesia for the treatment of spasticity and pain in a patient with maple syrup urine disease.Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A.Botulinum Toxin in Aesthetic Medicine: Myths and Realities.Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes.Botulinum neurotoxin formulations: overcoming the confusion.Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending storyBotulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease
P2860
Q26766728-89404B29-70C1-468A-836D-FF615D3F8F9AQ33822481-C193E278-1BC5-4C7F-83F1-A62979A18E85Q33925713-CDA640C7-65DD-4877-8A4E-1B8C04BCF7BBQ34352934-FBC6F0D4-D275-4988-BA04-DEFA6546BA99Q34443526-02F7DDC7-A381-4090-8E7F-B7F5EEA5465BQ34443530-FDAF66A2-35D4-4AEC-9688-7B34AFF7662AQ35050218-2FBBDBD2-954D-4DAA-BC14-B6063856E3AFQ35681898-C1A86429-1AD4-4110-9E7F-9571A6A5E2B1Q36555421-2A178603-91A1-4B7E-846C-8090BF85E808Q36828130-CB6E31D2-4F9C-468D-AD3E-687460F651F7Q37844682-CA59F8E6-D515-4AB6-8567-2D6D7DCE60B4Q37883035-DB9DBD4B-F15B-42D4-997B-4AF9C2A3403DQ38178982-78EA6575-F296-4EDF-A43E-CDF9995CEFDBQ38428227-55A060D0-8AEE-42BD-B886-482441A185A2Q38826378-C456AFEE-0883-4028-894E-3546A22980ECQ42218063-3D606208-852B-4929-82C2-AE1114E98CADQ43185582-79A4307C-7628-4667-8D49-031123DC1927Q44968846-17FE13B0-D52B-49B3-B290-4A76934D2F22Q47671772-7F8861DE-88C0-49B5-AA52-E511F2EAE285Q51959643-25F7C682-144D-428A-BDA6-A9F43D83DA2DQ55260245-F23BFFD9-37C4-410F-A11F-E37ACDFB63FAQ59153415-2CDAEADE-FAB3-418E-B2FD-111BFDF0F4A7Q59153428-0E82A1B7-130A-4985-B0E0-23A97B347DFE
P2860
Using translational medicine to understand clinical differences between botulinum toxin formulations.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Using translational medicine t ...... botulinum toxin formulations.
@ast
Using translational medicine t ...... botulinum toxin formulations.
@en
type
label
Using translational medicine t ...... botulinum toxin formulations.
@ast
Using translational medicine t ...... botulinum toxin formulations.
@en
prefLabel
Using translational medicine t ...... botulinum toxin formulations.
@ast
Using translational medicine t ...... botulinum toxin formulations.
@en
P2093
P2860
P1476
Using translational medicine t ...... botulinum toxin formulations.
@en
P2093
P2860
P356
10.1111/J.1468-1331.2006.01649.X
P478
13 Suppl 4
P577
2006-12-01T00:00:00Z